The Valley Desk

NCT03972709 · Interventional trial

A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Overall registry status Terminated

Phase 2

Conditions Geographic Atrophy, Macular Degeneration, Age-Related

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov